Characterize Now with Proven Efficacy

LUMASON is the first and only approved ultrasound contrast agent indicated for use in pediatric and adult patients to characterize focal liver lesions1

In ultrasonography of the liver, LUMASON provides dynamic patterns of lesion-liver enhancement during all 3 phases

Scans
Scans

36-year-old female. A. 4.0 cm hypoechoic lesion B-mode sonography. B. LUMASON showed a peripheral enhancement with nodular contrast accumulations in the arterial phase. C. Slow progression of the enhancement from the periphery toward the center of the lesion, with a broader peripheral enhancement zone seen in the portal phase. D. During the late phase, the lesion is completely filled with contrast and appears hyperenhanced compared to the surrounding normal liver tissue. The enhancement pattern is typical for a hemangioma.

Ultrasound image is reprinted with permission from World Journal of Gastroenterology.3 Individual results may vary.

LUMASON contrast-enhanced ultrasound showed improvement in characterization of focal liver lesions when compared with unenhanced ultrasound1

Study A Sensitivity N=119 (patients with malignant lesions) Specificity N=140 (patients with benign lesions)
Reader 1 Reader 2 Reader 3 Reader 1 Reader 2 Reader 3
LUMASON % 87* 76* 92* 71 83* 73*
Non-contrast % 49 35 16 63 54 22
Difference (95% Cl) 38 (30, 54) 41 (29, 52) 76 (67, 84) 8 (-4, 21) 29 (21, 44) 51 (40, 61)
Study B Sensitivity N=124 (patients with malignant lesions) Specificity N=116 (patients with benign lesions)
Reader 4 Reader 5 Reader 6 Reader 4 Reader 5 Reader 6
LUMASON % 65 61* 47 72* 67* 88*
Non-contrast % 53 41 66 24 7 59
Difference (95% Cl) 12 (-1, 23) 20 (7, 32) -19 (-31, -7) 48 (35, 58) 60 (50, 70) 29 (18, 40)

*Statistically significant improvement from non-contrast (P<0.05 based on McNemar's test).

Doctor

The individuals who appear are for illustrative purposes only. Individual results may vary.